patient consent News
-
Segmed Ethics Committee Recap
Anonymized medical data sharing is necessary for the advancement of medicine, but it requires a tremendous amount of trust from all stakeholders. Patients need to trust that their healthcare providers are utilizing their data to advance innovations that will help them in the future. Healthcare providers such as health systems and hospitals must trust external stakeholders to use that data for ...
By Segmed, Inc.
-
RepliCel Ships DermaPrecise Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has shipped DermaPrecise Injector prototypes and consumables to an independent laboratory in Germany to conduct validation studies of injection parameters in various types of ...
-
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD). The first patient has consented to participate in the trial and ...
-
Five TAVR Patients Successfully Implanted with DurAVR Valve
Anteris reports successfully implanting five TAVR patients during the week of 14 November 2021 in a first-in-human (FIH) study to assess the DurAVR THV system for treating severe aortic stenosis. The study was carried out at the Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia. The transcatheter aortic valve replacement procedures for all five patients were successful and without any ...
-
CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs
The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy. Real-life data and Innovative Bioinformatic Algorithms (RIBA project) will enable the creation of a powerful environment to accelerate, de-risk, and improve the development of new ...
-
BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission. Q2 and Recent Business Highlights: ...
-
MassChallenge announces 30 digital health companies to join its 2019 cohort
At the end of the program the startups will get a chance to compete for more than $200,000 in prize money. Last week MassChallenge HealthTech unveiled the 30 digital health startups that will make up its 2019 cohort. The program gives the startups co-working office space and a tailored curriculum, with the primary goal of connecting startups to advisors, investors, pilots and research ...
By Epihunter NV
-
University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further research into combination therapy with Cesium-131 brachytherapy and surgical resection. The prospective series was conducted at the University Hospitals Cleveland Medical ...
By Isoray Inc.
-
Evolution of ePROM: Advancements, Concerns, and the Way Forward
Patients’ directly reported outcomes in certain rare and chronic diseases are considered reliable for understanding the disease’s natural history, palliative treatments that focus primarily on symptom control, and quality of life. Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness ...
-
Longenesis and Medtronic Study Finds Insulin Pumps Contribute to Better Quality of Life for Type 1 Diabetes Patients
Longenesis announced today the preliminary results from its study on Type 1 Diabetes care in partnership with Medtronic. In less than three months, more than 85 patients participated in the research study, providing qualitative and quantitative data on the quality of life for Type 1 diabetics using insulin pumps compared to daily insulin injections. The study sponsors used participant data to ...
By Longenesis
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you